AstraZeneca PLC (AZN)vsNurix Therapeutics Inc (NRIX)
AZN
AstraZeneca PLC
$169.51
+2.94%
HEALTHCARE · Cap: $263.78B
NRIX
Nurix Therapeutics Inc
$27.26
+2.10%
HEALTHCARE · Cap: $2.67B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8642% more annual revenue ($61.37B vs $701.94M). NRIX leads profitability with a 42.0% profit margin vs 17.0%. NRIX trades at a lower P/E of 10.1x. NRIX earns a higher WallStSmart Score of 65/100 (C+).
AZN
Buy62
out of 100
Grade: C+
NRIX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Intrinsic value data unavailable for NRIX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 83.1%
Revenue surging 8426.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
ROE of -61.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : NRIX
The strongest argument for NRIX centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.0% and operating margin at 83.1%. Revenue growth of 8426.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : NRIX
The primary concerns for NRIX are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while NRIX is a growth play — different risk/reward profiles.
NRIX carries more volatility with a beta of 1.82 — expect wider price swings.
NRIX is growing revenue faster at 8426.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
NRIX scores higher overall (65/100 vs 62/100), backed by strong 42.0% margins and 8426.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nurix Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?